comparemela.com

Page 6 - Nasdaq Snce News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Science 37 (NASDAQ:SNCE) Lowered to Hold at Zacks Investment Research

Science 37 (NASDAQ:SNCE – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Friday, Zacks.com reports. According to Zacks, “Science 37 Inc. provides operating system for agile clinical trials. Science 37 Inc., formerly known as LifeSci Acquisition II Corp., is based in […]

Science 37® to Present at the William Blair 42nd Annual

RESEARCH TRIANGLE PARK, N.C., May 25, 2022 (GLOBE NEWSWIRE) Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating Systemâ„¢,.

Critical Review: Science 37 (NASDAQ:SNCE) & iSpecimen (NASDAQ:ISPC)

Science 37 (NASDAQ:SNCE – Get Rating) and iSpecimen (NASDAQ:ISPC – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability and valuation. Valuation & Earnings This table compares Science 37 and iSpecimen’s […]

Science 37 to Report First Quarter 2022 Financial Results

RESEARCH TRIANGLE PARK, N.C., April 25, 2022 (GLOBE NEWSWIRE) Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating Systemâ„¢.

ProMIS Neurosciences (OTCMKTS:ARFXF) & Science 37 (NASDAQ:SNCE) Head to Head Contrast

Science 37 (NASDAQ:SNCE – Get Rating) and ProMIS Neurosciences (OTCMKTS:ARFXF – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability. Analyst Recommendations This is a breakdown of current recommendations […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.